Zura Bio Limited (NASDAQ:ZURA - Free Report) - Investment analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for shares of Zura Bio in a report issued on Tuesday, March 25th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.15). The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio's Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.53) EPS and FY2026 earnings at ($0.48) EPS.
Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter.
Other research analysts also recently issued reports about the stock. HC Wainwright restated a "neutral" rating and set a $5.00 price target on shares of Zura Bio in a report on Tuesday, December 24th. Cantor Fitzgerald reissued an "overweight" rating on shares of Zura Bio in a research note on Wednesday, December 11th. Oppenheimer reaffirmed an "outperform" rating and issued a $19.00 target price (down previously from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Chardan Capital dropped their price target on Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. Finally, Guggenheim restated a "buy" rating and set a $15.00 price objective on shares of Zura Bio in a research report on Wednesday, March 26th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $15.00.
Read Our Latest Stock Analysis on ZURA
Zura Bio Stock Performance
NASDAQ ZURA traded down $0.12 on Friday, reaching $1.18. The company's stock had a trading volume of 180,219 shares, compared to its average volume of 376,750. Zura Bio has a twelve month low of $1.07 and a twelve month high of $6.35. The firm's 50 day moving average is $1.45 and its two-hundred day moving average is $2.71. The stock has a market cap of $76.72 million, a PE ratio of -2.22 and a beta of 0.06.
Institutional Trading of Zura Bio
A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC boosted its stake in Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company's stock worth $58,000 after buying an additional 7,828 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after acquiring an additional 9,379 shares in the last quarter. Bank of America Corp DE increased its stake in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock valued at $103,000 after acquiring an additional 9,966 shares during the period. Rhumbline Advisers raised its position in Zura Bio by 37.3% in the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock worth $94,000 after purchasing an additional 10,231 shares in the last quarter. Finally, American Century Companies Inc. bought a new position in Zura Bio during the fourth quarter worth about $27,000. 61.14% of the stock is currently owned by institutional investors.
Zura Bio Company Profile
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
See Also
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
